MCID: THY128
MIFTS: 48

Thyroid Tumor

Categories: Endocrine diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Thyroid Tumor

MalaCards integrated aliases for Thyroid Tumor:

Name: Thyroid Tumor 58 28 5

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

UMLS via Orphanet 72 C0040136
Orphanet 58 ORPHA100087

Summaries for Thyroid Tumor

MalaCards based summary: Thyroid Tumor is related to follicular adenoma and thyroid carcinoma, familial medullary. An important gene associated with Thyroid Tumor is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and Disease. The drugs Hemostatics and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Related Diseases for Thyroid Tumor

Diseases related to Thyroid Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 397)
# Related Disease Score Top Affiliating Genes
1 follicular adenoma 30.1 RET PTEN HRAS BRAF
2 thyroid carcinoma, familial medullary 29.9 RET PRKAR1A KRAS BRAF
3 teratoma 29.8 PTEN KRAS AKT1
4 nodular goiter 29.6 RET HRAS BRAF
5 rectal benign neoplasm 29.5 PIK3CA KRAS HRAS
6 thyroid cancer, nonmedullary, 2 29.3 PTEN NRAS LRRC56 HRAS BRAF
7 adenoid cystic carcinoma 29.2 PTEN PIK3CA LRRC56 KRAS HRAS AKT1
8 adenoma 29.2 RET PRKAR1A PIK3CA KRAS HRAS BRAF
9 hashimoto thyroiditis 29.0 RET NRAS KRAS HRAS BRAF
10 differentiated thyroid carcinoma 28.9 RET NRAS KRAS HRAS BRAF
11 wilms tumor 1 28.8 PTEN KRAS HRAS BRAF AKT1
12 thyroid gland follicular carcinoma 28.8 RET PTEN PIK3CA NRAS HRAS BRAF
13 thyroid gland anaplastic carcinoma 28.4 RET PTEN PIK3CA NRAS HRAS BRAF
14 cowden syndrome 28.3 RET PTEN PRKAR1A PIK3CA KRAS HRAS
15 adenocarcinoma 28.3 RET PTEN PIK3CA KRAS HRAS BRAF
16 neurofibromatosis 28.2 RET PTEN NRAS KRAS HRAS BRAF
17 thyroid gland cancer 28.0 RET PTEN PIK3CA NRAS LRRC56 KRAS
18 squamous cell carcinoma 28.0 PTEN PIK3CA NRAS KRAS HRAS BRAF
19 renal cell carcinoma, nonpapillary 27.6 RET PTEN PIK3CA NRAS KRAS HRAS
20 breast cancer 27.1 RET PTEN PIK3CA NRAS LRRC56 KRAS
21 thyroid gland medullary carcinoma 11.1
22 multiple endocrine neoplasia, type iia 11.0
23 thyroid carcinoma 10.7
24 thyroid cancer, nonmedullary, 1 10.5
25 goiter 10.4
26 papillary carcinoma 10.4
27 trachea carcinoma in situ 10.2 KRAS HRAS
28 common bile duct neoplasm 10.2 KRAS HRAS
29 ampulla of vater benign neoplasm 10.2 KRAS HRAS
30 bladder urachal carcinoma 10.2 KRAS HRAS
31 cutaneous-skeletal hypophosphatemia syndrome 10.2 LRRC56 HRAS
32 urachus cancer 10.2 KRAS HRAS
33 adenosquamous lung carcinoma 10.2 KRAS HRAS
34 descending colon cancer 10.2 KRAS HRAS
35 mucinous intrahepatic cholangiocarcinoma 10.2 KRAS HRAS
36 sigmoid neoplasm 10.2 KRAS HRAS
37 appendiceal neoplasm 10.2 KRAS HRAS
38 pancreatic mucinous cystadenoma 10.2 KRAS HRAS
39 transverse colon cancer 10.2 KRAS HRAS
40 noonan syndrome-like disorder with loose anagen hair 1 10.2 KRAS HRAS
41 liver angiosarcoma 10.2 KRAS HRAS
42 ascending colon cancer 10.2 KRAS HRAS
43 mucinous lung adenocarcinoma 10.2 KRAS HRAS
44 cystadenofibroma 10.2 KRAS HRAS
45 endosalpingiosis 10.2 KRAS HRAS
46 ovarian mucinous neoplasm 10.2 KRAS HRAS
47 appendix adenocarcinoma 10.2 KRAS HRAS
48 multiple mucosal neuroma 10.2 RET PTEN
49 skin lipoma 10.2 RET PTEN
50 large cell carcinoma with rhabdoid phenotype 10.2 KRAS HRAS

Graphical network of the top 20 diseases related to Thyroid Tumor:



Diseases related to Thyroid Tumor

Symptoms & Phenotypes for Thyroid Tumor

GenomeRNAi Phenotypes related to Thyroid Tumor according to GeneCards Suite gene sharing:

25 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.99 HRAS BRAF PIK3CA KRAS
2 Decreased viability GR00055-A-2 10.99 HRAS BRAF PIK3CA KRAS
3 Decreased viability GR00055-A-3 10.99 KRAS
4 Decreased viability GR00106-A-0 10.99 KRAS
5 Decreased viability GR00221-A-1 10.99 AKT1 HRAS NRAS PRKAR1A PIK3CA RET
6 Decreased viability GR00221-A-2 10.99 AKT1 HRAS PRKAR1A PIK3CA RET KRAS
7 Decreased viability GR00221-A-3 10.99 AKT1 HRAS NRAS PRKAR1A
8 Decreased viability GR00221-A-4 10.99 AKT1 PRKAR1A BRAF PIK3CA RET
9 Decreased viability GR00249-S 10.99 AKT1 BRAF
10 Decreased viability GR00301-A 10.99 BRAF RET KRAS
11 Decreased viability GR00381-A-1 10.99 BRAF KRAS
12 Decreased viability GR00402-S-2 10.99 PIK3CA RET
13 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.92 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.92 PRKAR1A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.92 RET
16 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.92 BRAF
17 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.92 PTEN
18 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.92 PTEN
19 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.92 PTEN
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.92 RET
21 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.92 HRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.92 PRKAR1A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.92 AKT1 RET
24 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.92 PTEN
25 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.92 KRAS
26 Increased shRNA abundance (Z-score > 2) GR00366-A-28 9.92 HRAS RET
27 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.92 NRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.92 PTEN
29 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.92 BRAF
30 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.92 RET
31 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.92 AKT1 PIK3CA RET
32 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.92 KRAS PTEN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.92 PTEN
34 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.92 AKT1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.92 NRAS
36 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.92 RET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.92 HRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.92 AKT1 RET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.92 HRAS PTEN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.92 PTEN
41 Increased transferrin (TF) endocytosis (mild increase), increased transferrin (TF) endosome elongation GR00363-A 8.65 HRAS

MGI Mouse Phenotypes related to Thyroid Tumor:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 AKT1 BRAF HRAS KRAS LRRC56 NIBAN1
2 growth/size/body region MP:0005378 10.31 AKT1 BRAF HRAS KRAS LRRC56 NIBAN1
3 neoplasm MP:0002006 10.24 AKT1 BRAF HRAS KRAS NRAS PIK3CA
4 normal MP:0002873 10.24 AKT1 BRAF HRAS KRAS NIBAN1 NRAS
5 cardiovascular system MP:0005385 10.2 AKT1 BRAF HRAS KRAS LRRC56 NIBAN1
6 muscle MP:0005369 10.18 AKT1 BRAF HRAS KRAS PIK3CA PRKAR1A
7 endocrine/exocrine gland MP:0005379 10.18 AKT1 BRAF HRAS KRAS NRAS PIK3CA
8 digestive/alimentary MP:0005381 10.15 BRAF HRAS KRAS NRAS PIK3CA PRKAR1A
9 immune system MP:0005387 10.14 AKT1 BRAF KRAS LRRC56 NIBAN1 NRAS
10 cellular MP:0005384 10.13 AKT1 BRAF KRAS NRAS PIK3CA PRKAR1A
11 embryo MP:0005380 10.11 AKT1 BRAF KRAS NRAS PIK3CA PRKAR1A
12 behavior/neurological MP:0005386 10.09 AKT1 BRAF HRAS KRAS NRAS PIK3CA
13 liver/biliary system MP:0005370 10.04 AKT1 BRAF KRAS NRAS PRKAR1A PTEN
14 limbs/digits/tail MP:0005371 10.03 BRAF KRAS NRAS PRKAR1A PTEN RET
15 respiratory system MP:0005388 10.02 AKT1 BRAF HRAS KRAS LRRC56 PRKAR1A
16 pigmentation MP:0001186 10 BRAF KRAS NRAS PRKAR1A PTEN
17 reproductive system MP:0005389 9.97 AKT1 BRAF KRAS LRRC56 NIBAN1 PIK3CA
18 skeleton MP:0005390 9.91 AKT1 BRAF HRAS KRAS NRAS PIK3CA
19 hematopoietic system MP:0005397 9.81 AKT1 BRAF KRAS NIBAN1 NRAS PRKAR1A
20 mortality/aging MP:0010768 9.7 AKT1 BRAF HRAS KRAS LRRC56 NRAS
21 integument MP:0010771 9.32 AKT1 BRAF HRAS KRAS LRRC56 NIBAN1

Drugs & Therapeutics for Thyroid Tumor

Drugs for Thyroid Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hemostatics Phase 3
2
Dexmedetomidine Approved, Experimental, Vet_approved 86347-14-0, 113775-47-6 68602 5311068
3
Remifentanil Approved 132875-61-7 60815
4
Desflurane Approved 57041-67-5 42113
5
Iodine Approved, Investigational 7553-56-2 807
6
Cadexomer iodine Experimental 94820-09-4
7 Analgesics
8 Neurotransmitter Agents
9 Adrenergic alpha-Agonists
10 Adrenergic Agonists
11 Adrenergic Agents
12 Anesthetics, Inhalation
13 Anesthetics, General
14 Hypnotics and Sedatives
15 Analgesics, Opioid
16 Analgesics, Non-Narcotic
17 Narcotics
18 Anesthetics

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy Unknown status NCT01551914 Phase 3
2 Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry Unknown status NCT01668238
3 Clinical Benefits of Reduced Subcutaneous Dissection in Endoscopic Thyroidectomy Unknown status NCT01338597
4 Contrast-enhanced Ultrasound in Thyroid Tumor by Sonozoid Completed NCT04574258
5 Using Circulating Biomarkers to Identify Thyroid Cancer From the Patients With Thyroid Nodules Completed NCT04594720
6 Effect of Dexmedetomidine Infusion for Postoperative Outcome and Smooth Emergence After Thyroidectomy Completed NCT02412150 Desflurane;Remifentanil;Dexmedetomidine;Normal saline
7 Prospective and Retrospective Thyroid Cancer Database Recruiting NCT04031638
8 Effect of Improved Endotracheal Intubation Procedure Combined With Early Oral Intake on Postoperative Recovery Quality of Patients Undergoing Intraoperative Recurrent Laryngeal Nerve Monitoring. Not yet recruiting NCT05624463
9 Effect of Early Postoperative Drinking Water on Postoperative Recovery Quality of Patients With Thyroid Surgery Not yet recruiting NCT05532384

Search NIH Clinical Center for Thyroid Tumor

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2b
lenvatinib
levothyroxine
Levothyroxine Sodium
liothyronine
liothyronine sodium
sorafenib
Thyroglobulin
THYROID (BEEF)
thyroid (USP)
THYROID PWDR
thyrotropin alfa
Vandetanib

Genetic Tests for Thyroid Tumor

Genetic tests related to Thyroid Tumor:

# Genetic test Affiliating Genes
1 Thyroid Tumor 28

Anatomical Context for Thyroid Tumor

Organs/tissues related to Thyroid Tumor:

MalaCards : Thyroid, Lymph Node, Breast, Thymus, Lung, Trachea, Endothelial

Publications for Thyroid Tumor

Articles related to Thyroid Tumor:

(show top 50) (show all 1660)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
3
Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors. 5
24628546 2014
4
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. 5
23406027 2013
5
AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines. 5
23056499 2012
6
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. 5
22025146 2012
7
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. 5
21470995 2011
8
Targeted therapies for thyroid tumors. 5
21455200 2011
9
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. 5
20847059 2010
10
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. 5
20368568 2010
11
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. 5
20065189 2010
12
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 5
19773371 2009
13
Phase II trial of sorafenib in metastatic thyroid cancer. 5
19255327 2009
14
Phase II trial of sorafenib in advanced thyroid cancer. 5
18541894 2008
15
Hyperactive Ras in developmental disorders and cancer. 5
17384584 2007
16
Molecular biology of the MEN2 gene. 5
9681850 1998
17
Thyroid tuberculosis diagnosed as papillary thyroid carcinoma with fever of unknown origin. 62
34657776 2022
18
Intrathyroidal Thymic Carcinoma: A Retrospective Case Series Study. 62
36408572 2022
19
Anesthetic management of trachea with huge thyroid tumor compression: A case report. 62
36456440 2022
20
A Case of Thyroid Carcinoma Showing Thymus-Like Differentiation With Breast Cancer Susceptibility Gene 2 Mutation: A Case Report and Literature Review. 62
36426335 2022
21
Case Report: Giant Thyroid Angiolipoma-Challenging Clinical Diagnosis and Novel Genetic Alterations. 62
36255668 2022
22
Downhill varices in the hypopharynx due to huge thyroid tumor: a case report. 62
36273906 2022
23
Using the Baidu index to understand Chinese interest in thyroid related diseases. 62
36229549 2022
24
FBCU-Net: A fine-grained context modeling network using boundary semantic features for medical image segmentation. 62
36240598 2022
25
Ferroptosis Inducers in Thyroid Cancer. 62
36195678 2022
26
A computed tomography-based radiomic nomogram for predicting lymph node metastasis in patients with early-stage papillary thyroid carcinoma. 62
34859689 2022
27
[Risk factors for recurrence and survival analysis in locally advanced T4a papillary thyroid carcinoma after R0 resection]. 62
36177557 2022
28
Follicular Neoplasm of Thyroid Revisited: Current Differential Diagnosis and the Impact of Molecular Testing. 62
36102526 2022
29
Anaplastic thyroid tumor as an embolic source of metastasis. 62
35936021 2022
30
Thyroid metastasis revealing a lung adenocarcinoma: A case report and review of the literature. 62
36055168 2022
31
Subcutaneous axillary primary epithelioid hemangioendothelioma: report of a rare case. 62
36083389 2022
32
ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis. 62
36070054 2022
33
Survival-based bioinformatics analysis to identify hub long non-coding RNAs along with lncRNA-miRNA-mRNA network for potential diagnosis/prognosis of thyroid cancer. 62
36149574 2022
34
MiR-203a-3p, miR-204-3p, miR-222-3p as useful diagnostic and prognostic tool for thyroid neoplasia spectrum. 62
36103016 2022
35
Safety and Efficacy of Transoral Robotic Thyroidectomy for Thyroid Tumor: A Systematic Review and Meta-Analysis. 62
36077768 2022
36
Assessment of Preoperative TSH Serum Level and Thyroid Cancer Occurrence in Patients with AUS/FLUS Thyroid Nodule Diagnosis. 62
36009464 2022
37
Retraction notice to "Transnasal humidified rapid-insufflation ventilatory exchange can be utilized in tracheal stenosis caused by thyroid tumor" [J. Clin. Anesth. 62(2020) 109727]. 62
35396112 2022
38
Fumarate Hydratase is a Novel Gene for Familial Non-Medullary Thyroid Cancer. 62
35751867 2022
39
Primary pulmonary epithelioid angiosarcoma with thyroid tumor history: A case report and literature review. 62
35761817 2022
40
Nomograms based on preoperative multimodal ultrasound of papillary thyroid carcinoma for predicting central lymph node metastasis. 62
35226156 2022
41
Hypofractionated radiation therapy of a thyroid tumor in a pet raccoon (Procyon lotor). 62
35784773 2022
42
Towards Optimized Bioavailability of 99mTc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity. 62
34750717 2022
43
Thyroid tumor ratio: Improving the assessment of the impact of size in pediatric thyroid cancer. 62
35322489 2022
44
MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer. 62
35659780 2022
45
Extracellular vesicles from thyroid cancer harbor a functional machinery involved in extracellular matrix remodeling. 62
35849996 2022
46
Nerve autofluorescence under near-ultraviolet light: cutting-edge technology for intra-operative neural tissue visualization in 17 patients. 62
34694489 2022
47
Identification of an interactome network between lncRNAs and miRNAs in thyroid cancer reveals SPTY2D1-AS1 as a new tumor suppressor. 62
35562181 2022
48
The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer. 62
35489753 2022
49
Use of ultrasonographic shear wave measurements to diagnose thyroid metastasis from breast carcinoma. 62
35644558 2022
50
Giant cervical goiter in Hashimoto's thyroiditis: A case report. 62
35538703 2022

Variations for Thyroid Tumor

ClinVar genetic disease variations for Thyroid Tumor:

5 (show all 42)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KRAS NM_033360.4(KRAS):c.182A>C (p.Gln61Pro) SNV Pathogenic
375966 rs121913240 GRCh37: 12:25380276-25380276
GRCh38: 12:25227342-25227342
2 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>C (p.Gly12Arg) SNV Pathogenic
375961 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
3 KRAS NM_004985.5(KRAS):c.181C>A (p.Gln61Lys) SNV Pathogenic
177777 rs121913238 GRCh37: 12:25380277-25380277
GRCh38: 12:25227343-25227343
4 KRAS NM_033360.4(KRAS):c.37G>A (p.Gly13Ser) SNV Pathogenic
375968 rs121913535 GRCh37: 12:25398282-25398282
GRCh38: 12:25245348-25245348
5 KRAS NM_004985.5(KRAS):c.182A>T (p.Gln61Leu) SNV Pathogenic
45116 rs121913240 GRCh37: 12:25380276-25380276
GRCh38: 12:25227342-25227342
6 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>T (p.Gly12Val) SNV Pathogenic
12600 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
7 KRAS NM_004985.5(KRAS):c.437C>T (p.Ala146Val) SNV Pathogenic
375962 rs1057519725 GRCh37: 12:25378561-25378561
GRCh38: 12:25225627-25225627
8 HRAS, LRRC56 NM_005343.4(HRAS):c.182A>G (p.Gln61Arg) SNV Pathogenic
160364 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
9 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>C (p.Gly13Arg) SNV Pathogenic
35554 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
10 KRAS NM_004985.5(KRAS):c.182A>G (p.Gln61Arg) SNV Pathogenic
45115 rs121913240 GRCh37: 12:25380276-25380276
GRCh38: 12:25227342-25227342
11 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Pathogenic
12606 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
12 KRAS NM_004985.5(KRAS):c.35G>T (p.Gly12Val) SNV Pathogenic
12583 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
13 KRAS NM_004985.5(KRAS):c.34G>T (p.Gly12Cys) SNV Pathogenic
12578 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
14 KRAS NM_004985.5(KRAS):c.34G>C (p.Gly12Arg) SNV Pathogenic
12579 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
15 KRAS NM_004985.5(KRAS):c.38G>A (p.Gly13Asp) SNV Pathogenic
12580 rs112445441 GRCh37: 12:25398281-25398281
GRCh38: 12:25245347-25245347
16 RET NM_020975.6(RET):c.2753T>C (p.Met918Thr) SNV Pathogenic
13919 rs74799832 GRCh37: 10:43617416-43617416
GRCh38: 10:43121968-43121968
17 KRAS NM_004985.5(KRAS):c.34G>A (p.Gly12Ser) SNV Pathogenic
12584 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
18 KRAS NM_004985.5(KRAS):c.37G>C (p.Gly13Arg) SNV Pathogenic
12593 rs121913535 GRCh37: 12:25398282-25398282
GRCh38: 12:25245348-25245348
19 KRAS NM_004985.5(KRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic
12582 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
20 RET NM_020975.6(RET):c.1902C>G (p.Cys634Trp) SNV Likely Pathogenic
13918 rs77709286 GRCh37: 10:43609950-43609950
GRCh38: 10:43114502-43114502
21 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely Pathogenic
12602 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
22 KRAS NM_004985.5(KRAS):c.38G>T (p.Gly13Val) SNV Likely Pathogenic
45124 rs112445441 GRCh37: 12:25398281-25398281
GRCh38: 12:25245347-25245347
23 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely Pathogenic
12613 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
24 BRAF NM_004333.6(BRAF):c.1801A>G (p.Lys601Glu) SNV Likely Pathogenic
13966 rs121913364 GRCh37: 7:140453134-140453134
GRCh38: 7:140753334-140753334
25 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely Pathogenic
12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
26 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His) SNV Likely Pathogenic
373003 rs121913255 GRCh37: 1:115256528-115256528
GRCh38: 1:114713907-114713907
27 BRAF NM_004333.6(BRAF):c.1802A>C (p.Lys601Thr) SNV Likely Pathogenic
44818 rs397507484 GRCh37: 7:140453133-140453133
GRCh38: 7:140753333-140753333
28 HRAS, LRRC56 NM_005343.4(HRAS):c.183G>T (p.Gln61His) SNV Likely Pathogenic
376318 rs121913496 GRCh37: 11:533873-533873
GRCh38: 11:533873-533873
29 HRAS, LRRC56 NM_005343.4(HRAS):c.182A>C (p.Gln61Pro) SNV Likely Pathogenic
376322 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
30 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro) SNV Likely Pathogenic
280409 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
31 PIK3CA NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val) SNV Likely Pathogenic
376485 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
32 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr) SNV Likely Pathogenic
376486 rs1057519937 GRCh37: 3:178952073-178952073
GRCh38: 3:179234285-179234285
33 HRAS, LRRC56 NM_005343.4(HRAS):c.182A>T (p.Gln61Leu) SNV Likely Pathogenic
376033 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
34 PIK3CA NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp) SNV Likely Pathogenic
156446 rs587777790 GRCh37: 3:178917478-178917478
GRCh38: 3:179199690-179199690
35 PIK3CA NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile) SNV Likely Pathogenic
179173 rs121913283 GRCh37: 3:178952074-178952074
GRCh38: 3:179234286-179234286
36 KRAS NM_004985.5(KRAS):c.183A>T (p.Gln61His) SNV Likely Pathogenic
45117 rs17851045 GRCh37: 12:25380275-25380275
GRCh38: 12:25227341-25227341
37 HRAS, LRRC56 NM_005343.4(HRAS):c.181C>G (p.Gln61Glu) SNV Likely Pathogenic
376444 rs28933406 GRCh37: 11:533875-533875
GRCh38: 11:533875-533875
38 BRAF NM_004333.6(BRAF):c.1803A>C (p.Lys601Asn) SNV Likely Pathogenic
376286 rs121913365 GRCh37: 7:140453132-140453132
GRCh38: 7:140753332-140753332
39 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu) SNV Likely Pathogenic
376487 rs1057519936 GRCh37: 3:178952072-178952072
GRCh38: 3:179234284-179234284
40 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu) SNV Likely Pathogenic
375874 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
41 AKT1 NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys) SNV Likely Pathogenic
13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214
42 DHX32 NM_018180.3(DHX32):c.798T>G (p.Ile266Met) SNV Uncertain Significance
1344808 GRCh37: 10:127548223-127548223
GRCh38: 10:125859654-125859654

Expression for Thyroid Tumor

Search GEO for disease gene expression data for Thyroid Tumor.

Pathways for Thyroid Tumor

Pathways related to Thyroid Tumor according to GeneCards Suite gene sharing:

(show top 50) (show all 180)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 PTEN PRKAR1A NRAS KRAS HRAS BRAF
2
Show member pathways
13.84 PTEN PRKAR1A PIK3CA NRAS KRAS HRAS
3
Show member pathways
13.83 PTEN PRKAR1A NRAS KRAS HRAS BRAF
4 13.75 AKT1 BRAF HRAS KRAS NRAS PIK3CA
5
Show member pathways
13.58 PRKAR1A PIK3CA NRAS KRAS HRAS AKT1
6
Show member pathways
13.56 AKT1 BRAF HRAS KRAS NRAS PRKAR1A
7
Show member pathways
13.54 PIK3CA NRAS KRAS HRAS BRAF AKT1
8
Show member pathways
13.53 PTEN PIK3CA NRAS KRAS HRAS AKT1
9
Show member pathways
13.51 PTEN PRKAR1A PIK3CA NRAS KRAS HRAS
10
Show member pathways
13.45 AKT1 BRAF HRAS KRAS NRAS PIK3CA
11
Show member pathways
13.37 AKT1 HRAS KRAS NRAS PRKAR1A PTEN
12
Show member pathways
13.35 PTEN PRKAR1A NRAS KRAS HRAS AKT1
13
Show member pathways
13.34 PRKAR1A PIK3CA NRAS KRAS HRAS AKT1
14
Show member pathways
13.33 PRKAR1A NRAS KRAS HRAS BRAF AKT1
15
Show member pathways
13.33 AKT1 BRAF HRAS KRAS NRAS PIK3CA
16
Show member pathways
13.32 PRKAR1A NRAS KRAS HRAS BRAF AKT1
17
Show member pathways
13.15 PTEN NRAS KRAS HRAS BRAF AKT1
18
Show member pathways
13.09 PRKAR1A NRAS KRAS HRAS AKT1
19
Show member pathways
13.04 PIK3CA NRAS KRAS HRAS AKT1
20
Show member pathways
13.03 PTEN PIK3CA NRAS KRAS HRAS AKT1
21
Show member pathways
12.96 PTEN PRKAR1A NRAS KRAS HRAS BRAF
22
Show member pathways
12.92 PIK3CA NRAS KRAS HRAS BRAF AKT1
23
Show member pathways
12.91 PIK3CA NRAS KRAS HRAS BRAF AKT1
24
Show member pathways
12.91 PRKAR1A PIK3CA NRAS KRAS HRAS BRAF
25
Show member pathways
12.9 AKT1 BRAF HRAS KRAS NRAS PIK3CA
26
Show member pathways
12.88 PTEN PIK3CA NRAS KRAS HRAS BRAF
27
Show member pathways
12.87 AKT1 BRAF HRAS KRAS NRAS PIK3CA
28 12.85 TNS3 PIK3CA NRAS KRAS HRAS BRAF
29
Show member pathways
12.84 AKT1 HRAS PIK3CA PRKAR1A PTEN
30
Show member pathways
12.84 PIK3CA NRAS KRAS HRAS BRAF
31
Show member pathways
12.82 PTEN PRKAR1A PIK3CA NRAS KRAS HRAS
32
Show member pathways
12.81 AKT1 HRAS KRAS NRAS
33
Show member pathways
12.8 PRKAR1A NRAS KRAS HRAS
34
Show member pathways
12.76 NRAS KRAS HRAS BRAF AKT1
35
Show member pathways
12.76 NRAS KRAS HRAS BRAF AKT1
36
Show member pathways
12.76 AKT1 BRAF HRAS KRAS NRAS PRKAR1A
37
Show member pathways
12.74 PIK3CA NRAS KRAS HRAS
38
Show member pathways
12.74 PRKAR1A NRAS KRAS HRAS BRAF AKT1
39 12.73 PTEN PIK3CA HRAS AKT1
40
Show member pathways
12.72 PRKAR1A NRAS KRAS HRAS BRAF AKT1
41
Show member pathways
12.71 NRAS KRAS HRAS BRAF
42
Show member pathways
12.71 AKT1 HRAS KRAS NRAS PIK3CA
43
Show member pathways
12.69 PIK3CA NRAS KRAS HRAS AKT1
44
Show member pathways
12.69 PTEN PIK3CA NRAS KRAS HRAS BRAF
45
Show member pathways
12.68 PIK3CA NRAS KRAS HRAS BRAF
46
Show member pathways
12.66 BRAF HRAS KRAS NRAS PIK3CA
47
Show member pathways
12.59 PTEN PIK3CA HRAS AKT1
48
Show member pathways
12.56 PTEN PIK3CA HRAS BRAF AKT1
49
Show member pathways
12.54 PIK3CA NRAS KRAS HRAS AKT1
50
Show member pathways
12.54 PIK3CA NRAS KRAS HRAS AKT1

GO Terms for Thyroid Tumor

Biological processes related to Thyroid Tumor according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.13 AKT1 BRAF HRAS KRAS RET
2 positive regulation of peptidyl-serine phosphorylation GO:0033138 10 PIK3CA BRAF AKT1
3 Ras protein signal transduction GO:0007265 9.99 NRAS KRAS HRAS
4 phosphorylation GO:0016310 9.98 RET PRKAR1A PIK3CA BRAF AKT1
5 protein kinase B signaling GO:0043491 9.88 PTEN PIK3CA AKT1
6 negative regulation of neuron apoptotic process GO:0043524 9.86 PIK3CA KRAS HRAS BRAF
7 epidermal growth factor receptor signaling pathway GO:0007173 9.85 AKT1 BRAF PIK3CA
8 anoikis GO:0043276 9.8 PIK3CA AKT1
9 phosphatidylinositol 3-kinase signaling GO:0014065 9.8 PTEN PIK3CA AKT1
10 positive regulation of protein phosphorylation GO:0001934 9.61 NIBAN1 KRAS HRAS BRAF AKT1
11 regulation of axon regeneration GO:0048679 9.46 PTEN BRAF
12 cellular response to decreased oxygen levels GO:0036294 9.33 PTEN AKT1
13 MAPK cascade GO:0000165 9.32 RET NRAS KRAS HRAS BRAF

Molecular functions related to Thyroid Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GDP binding GO:0019003 9.8 NRAS KRAS HRAS
2 kinase activity GO:0016301 9.8 RET PRKAR1A PIK3CA BRAF AKT1
3 G protein activity GO:0003925 9.43 NRAS KRAS HRAS
4 protein serine/threonine kinase activator activity GO:0043539 9.33 PIK3CA KRAS HRAS
5 nucleotide binding GO:0000166 9.23 RET PRKAR1A PIK3CA NRAS KRAS HRAS

Sources for Thyroid Tumor

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....